Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Effect of Metformin As an Adjunct Therapy in Adolescents With Type 1 Diabetes Publisher



Setoodeh A1 ; Didban A2 ; Rabbani A3 ; Sayarifard A4 ; Abbasi F5 ; Sayarifard F5 ; Hoseinzade F6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Paediatrics, Endocrinologist, Growth and Development Research Center, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Paediatrics, Endocrinologist, Qazvin University of Medical Sciences, Qazvin, Iran
  3. 3. Department of Paediatrics, Endocrinologist, Children’s medical center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Paediatrics, Preventive and Community Medicine specialist, Growth and Development Research Center, Children's Medical Center, Center for Academic and Health Policy, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Paediatrics, Endocrinologist, Growth and Developmental Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Clinical Nutrition, Nutrition and Food Sciences Research Center, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

Source: Journal of Clinical and Diagnostic Research Published:2017


Abstract

Introduction: The strict control of blood glucose levels in adolescents with Type 1 Diabetes Mellitus (T1DM) is accompanied with a considerable long term decrease in microvasular and macrovascular complications. Aim: This study was conducted to investigate the effect of metformin as an adjunct therapy in adolescents with poorly controlled Type 1 diabetes. Materials and Methods: It was a quasi-experimental (an uncontrolled before and after) study. The study population consisted of the patients aged over 10 years with T1DM. Metformin tablet was added to patient’s insulin therapy for 12 months. Haemoglobin A1c protein was measured in the beginning of the study and repeated with three months intervals till the end of it. Insulin dosage, Body Mass Index (BMI), serum, lipid, creatinine and lactate level were measured twice; in the beginning of the study and at the end of it (after 12 months). Data was analysed by SPSS (version 18) software. Paired-t-test, Wilcoxon signed ranks test and Repeated Measure ANOVA were used to examine the study’s hypothesis. A p-value <0.05 was considered as significant. Results: Twenty nine patients were included in the study. HbA1c level and insulin dosage was significantly reduced (p<0.001) after one month of metformin as an adjunct therapy. Serum lipid was decreased (p=0.7). Weight (p<0.001) and BMI (p=0.007) were increased. Conclusion: Adjunctive metformin therapy reduced HbA1c value and the insulin dosage received in adolescents with T1DM. © 2017, Journal of Clinical and Diagnostic Research. All rights reserved.
Related Docs
1. Benefits of Metformin Add-On Insulin Therapy (Mait) for Hba1c and Lipid Profile in Adolescents With Type 1 Diabetes Mellitus: Preliminary Report From a Double-Blinded, Placebo-Controlled, Randomized Clinical Trial, Journal of Pediatric Endocrinology and Metabolism (2022)
2. Metformin Therapy Reduces Obesity Indices in Children and Adolescents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, Childhood Obesity (2020)